Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Alkermes plc’s stock clocked out at $31.01, down -1.26% from its previous closing price of $31.41. In other words, the price has decreased by -$1.26 from its previous closing price. On the day, 3.35 million shares were traded. ALKS stock price reached its highest trading level at $31.735 during the session, while it also had its lowest trading level at $30.6.
Ratios:
To gain a deeper understanding of ALKS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.43. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on November 11, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
On September 26, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $44.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Hopkinson Craig C. sold 9,000 shares for $30.38 per share. The transaction valued at 273,442 led to the insider holds 69,740 shares of the business.
Hopkinson Craig C. bought 9,000 shares of ALKS for $273,442 on Nov 03 ’25. On Oct 15 ’25, another insider, Hopkinson Craig C., who serves as the EVP R&D, Chief Medical Officer of the company, sold 9,000 shares for $31.53 each. As a result, the insider received 283,776 and left with 73,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALKS now has a Market Capitalization of 5120293888 and an Enterprise Value of 4080777984. As of this moment, Alkermes’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.34, and their Forward P/E ratio for the next fiscal year is 18.77. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.37 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 2.682 whereas that against EBITDA is 10.498.
Stock Price History:
The Beta on a monthly basis for ALKS is 0.49, which has changed by 0.10003543 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, ALKS has reached a high of $36.45, while it has fallen to a 52-week low of $25.17. The 50-Day Moving Average of the stock is 3.25%, while the 200-Day Moving Average is calculated to be 2.16%.
Shares Statistics:
It appears that ALKS traded 2.25M shares on average per day over the past three months and 3345070 shares per day over the past ten days. A total of 165.10M shares are outstanding, with a floating share count of 161.12M. Insiders hold about 2.46% of the company’s shares, while institutions hold 102.53% stake in the company. Shares short for ALKS as of 1761868800 were 15896950 with a Short Ratio of 7.06, compared to 1759190400 on 15214415. Therefore, it implies a Short% of Shares Outstanding of 15896950 and a Short% of Float of 13.96.
Earnings Estimates
Alkermes plc (ALKS) is currently under the scrutiny of 4.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.38, with high estimates of $0.38 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.22 and $1.43 for the fiscal current year, implying an average EPS of $1.93. EPS for the following year is $2.32, with 1.0 analysts recommending between $2.32 and $2.32.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $378.57M. It ranges from a high estimate of $400.84M to a low estimate of $357M. As of. The current estimate, Alkermes plc’s year-ago sales were $429.99MFor the next quarter, 15 analysts are estimating revenue of $378.72M. There is a high estimate of $418.92M for the next quarter, whereas the lowest estimate is $329.83M.
A total of 15 analysts have provided revenue estimates for ALKS’s current fiscal year. The highest revenue estimate was $1.49B, while the lowest revenue estimate was $1.45B, resulting in an average revenue estimate of $1.47B. In the same quarter a year ago, actual revenue was $1.56BBased on 11 analysts’ estimates, the company’s revenue will be $1.81B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.54B.
